Noticias y Actividades de Mineralys Therapeutics

Mineralys Therapeutics es una de las ...

• Russell 3000;
• TOB Iconic 10,000.

Mineralys Therapeutics es una empresa que cotiza bajo el símbolo de cotización MLYS (US).

Ver el organigrama con sus 19 ejecutivos principales

Biografías más buscadas en Mineralys Therapeutics

• Jon Congleton, Chief Executive Officer
• Daphne Karydas, Director
• BT Slingsby, Director

Recientes movimientos de ejecutivos en Mineralys Therapeutics

• Stephen Djedjos, Senior Vice President, Clinical Development, ha dejado la empresa  (noticia publicada el 24 de enero de 2025).

Crear su alerta
para seguir los movimientos de los ejecutivos en Mineralys Therapeutics.

Mineralys Therapeutics tiene 2.347 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Johnson & Johnson Innovative Medicine DIA (Estados Unidos).

Popular M&A news in Biotecnología

• Attovia Therapeutics acaba de anunciar una recaudación de fondos de 90 millones de dólares. (publicado el 21 de abril de 2025).
• Transcarent and Accolade have merged  (publicado el 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 7 de abril de 2025).

Otros contactos sugeridos en el sector Biotecnología

• Kristina Burow - Director en Scholar Rock
• Steven Gillis - Chairman of the Board en VBI Vaccines
• Ali Behbahani - Non-Executive Director en Adaptimmune Therapeutics

Saber más sobre el sector Biotecnología

Últimos comunicados de prensa de Mineralys Therapeutics

• Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)
• Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
• Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
• Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo
• Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
• Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
• Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
• Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
• Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
• Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria
• View more press releases Close

Redes sociales sobre Mineralys Therapeutics

• Mineralys Therapeutics en Wikipedia, Google News y Yahoo Finance
• Mineralys Therapeutics en LinkedIn, Twitter y YouTube